Medicus Pharma submits Teverelix Phase 2b/3 registrational protocol to FDA

Medicus said it submitted an optimized seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix in advanced prostate cancer. The design starts with about 80 randomized patients and expands to about 608 if continuation criteria are met, targeting a registrational pathway in patients at increased cardiovascular risk and aiming to cut prior plans of about 1,500 patients. Medicus plans to seek a partner to fund execution, pending FDA feedback.